Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Launches Study of Cancer Test Adoption Patterns

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics this week said that has launched a study of its Epi proColon test to examine adoption patterns in the market.

The German molecular diagnostics firm launched the colorectal cancer test in Europe in 2009. It is currently being marketed by Epigenomics to privately insured individuals and self-payors in Germany, Austria, and Switzerland and through distributors in other markets, the firm said.

Epigenomics said that it expects the study to include around 300 primary care physicians and up to 3,000 patients getting the Epi proColon test in Germany and Switzerland.

"We expect the results of this study to help with both fine-tuning the positioning of the test in the self-payor market segment and in seeking general reimbursement under the public health care scheme," Juergen Beck, SVP of medical affairs for Epigenomics, said in a statement.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.